AVITA Medical Welcomes Dr. Tarnoff to Board of Directors

Author: Owen Jenkins Updated: 08-06-2025 04:22 PM

AVITA Medical Appoints New Board Director

AVITA Medical, Inc. (NASDAQ: RCEL), a leader in the acute wound care sector, has announced the addition of Dr. Michael Tarnoff, MD, FACS, as a non-executive director. This significant announcement marks a critical step in the Company’s growth and dedication to advancing innovative wound-healing technologies.

Strengthening Leadership with Expertise

Dr. Tarnoff brings a wealth of experience, having held executive positions at Tufts Medical Center and Medtronic, among other organizations. His appointment comes as the Company prioritizes patient-centric care, enhancing its impact within hospitals, burn centers, and trauma care settings. CEO Jim Corbett expressed enthusiasm about Dr. Tarnoff’s integration into the Board, highlighting his innovation-driven approach as essential for scaling AVITA's initiatives.

Guided by a Mission

Commenting on his new role, Dr. Tarnoff stated, "AVITA's commitment to transforming wound care resonates deeply with me. I look forward to guiding the organization as it continues to innovate and improve patient outcomes." His extensive background in clinical innovation positions him as a vital asset to the Company’s strategic vision.

Transition in Board Leadership

In a related development, AVITA Medical has also announced changes in its Board leadership. Cary Vance has been elected as the new Board Chair, succeeding Lou Panaccio, who is stepping down after ten years of distinguished service. Vance’s passion for innovation and his proven leadership in the healthcare industry are expected to significantly contribute to the Company’s future direction.

About AVITA Medical, Inc.

AVITA Medical is renowned for its pioneering technologies aimed at optimizing wound healing and expediting patient recovery. Central to its offerings is the RECELL® System, which utilizes a patient's own skin to create Spray-On Skin™ Cells to treat thermal burn wounds and trauma injuries effectively. This innovative approach ensures improved clinical outcomes across various care settings.

The RECELL System is also recognized internationally, receiving approvals in markets such as Australia and Europe to aid in the healing of skin defects and burns. In the U.S., AVITA holds exclusive rights to manufacture and market PermeaDerm®, as well as Cohealyx™, enhancing its extensive wound care portfolio.

AVITA Medical remains committed to its mission of redefining wound care and being at the forefront of medical advancements. The infusion of new leadership with Dr. Tarnoff and Mr. Vance strengthens the Company's resolve to innovate and expand its impact on patient care.

Frequently Asked Questions

Who has been appointed to AVITA Medical's Board of Directors?

Dr. Michael Tarnoff has been appointed as a non-executive director.

What leadership change has occurred at AVITA Medical?

Cary Vance has been elected as the new Board Chair, succeeding Lou Panaccio.

What is the main focus of AVITA Medical?

AVITA Medical focuses on delivering innovative solutions for acute wound care.

Where is the RECELL® System approved for use?

The RECELL® System is approved in the U.S., Australia, Europe, and Japan for various skin healing applications.

What technologies does AVITA Medical offer?

AVITA Medical offers the RECELL® System and holds exclusive rights to PermeaDerm® and Cohealyx™ for wound care.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.